
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6661348/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica, 2023, 108, 150-160.	3.5	10
2	Awareness of myeloma care and the global impact of treatment: An international internet-based prospective study. Journal of Oncology Pharmacy Practice, 2022, 28, 425-433.	0.9	0
3	One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica, 2022, 107, 1045-1053.	3.5	87
4	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i> -rearranged AML. Blood Advances, 2022, 6, 828-847.	5.2	5
5	Historical perspective and a glance into the antibody-based conditioning regimens: A new era in the horizon?. Blood Reviews, 2022, 52, 100892.	5.7	1
6	Cancer Management at Sites with Limited Resources: Challenges and Potential Solutions. , 2022, , 173-185.		2
7	Male-Specific Late Effects in Adult Hematopoletic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Transplantation and Cellular Therapy, 2022, 28,	1.2	5
8	in pact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 83.e1-83.e9.	1.2	9
9	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncology, 2022, 8, 404.	7.1	32
10	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplantation and Cellular Therapy, 2022, 28, 187.e1-187.e10.	1.2	3
11	Utilizing machine learning in predictive modeling: what's next?. Bone Marrow Transplantation, 2022, , .	2.4	3
12	Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplantation, 2022, 57, 1150-1163.	2.4	2
13	ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy. Transplantation and Cellular Therapy, 2022, 28, 523-529.	1.2	7
14	The Achilles' heel of cancer survivors: fundamentals of accelerated cellular senescence. Journal of Clinical Investigation, 2022, 132, .	8.2	18
15	Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. Transplantation and Cellular Therapy, 2022, 28, 712.e1-712.e8.	1.2	3
16	Hematopoietic stem cell transplantation in Saudi Arabia between 1984 and 2016: Experience from four leading tertiary care hematopoietic stem cell transplantation centers. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 169-178.	0.9	9
17	Noninfectious neurologic complications of hematopoietic cell transplantation: A systematic review. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 87-94.	0.9	10
18	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer, 2021, 127, 82-92.	4.1	15

#	Article	IF	CITATIONS
19	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. Cancer, 2021, 127, 609-618.	4.1	12
20	Systematic Review/Meta-Analysis on Efficacy of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease: An International Effort on Behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium. Transplantation and Cellular Therapy, 2021, 27, 167.e1-167.e12.	1.2	8
21	Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease. Transplantation and Cellular Therapy, 2021, 27, 177.e1-177.e8.	1.2	16
22	Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation. Transplantation and Cellular Therapy, 2021, 27, 270.e1-270.e6.	1.2	17
23	Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?. Blood Reviews, 2021, 46, 100742.	5.7	11
24	Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. Blood, 2021, 137, 556-568.	1.4	34
25	Risk of relapse in patients receiving azithromycin after allogeneic HSCT. Bone Marrow Transplantation, 2021, 56, 960-962.	2.4	3
26	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 6-20.	1.2	45
27	A Novel Combination for Graft-versus-Host-Disease Prophylaxis: Lessons Learned from the Birth of Sushi Burrito!. Acta Haematologica, 2021, 144, 126-129.	1.4	0
28	Emergency response to radiological and nuclear accidents and incidents. British Journal of Haematology, 2021, 192, 968-972.	2.5	18
29	Pregnancy with paroxysmal nocturnal hemoglobinuria: A case series with review of the literature. Saudi Journal of Medicine and Medical Sciences, 2021, 9, 178.	0.8	4
30	Should healthcare organisations offer ongoing rehabilitation services for patients undergoing haematopoietic cell transplant? A narrative review. International Journal of Health Governance, 2021, 26, 114-134.	1.2	2
31	Association of graft-versus-host-disease with neurologic complications: clinical paradigm and future directions. Bone Marrow Transplantation, 2021, 56, 1471-1473.	2.4	Ο
32	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. Transplantation and Cellular Therapy, 2021, 27, 267.e1-267.e5.	1.2	6
33	The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poorâ€risk cytogenetic abnormalities. EJHaem, 2021, 2, 249-256.	1.0	1
34	Role of gene therapy in Fanconi anemia: A systematic and literature review with future directions. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 290-301.	0.9	8
35	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 410-422.	1.2	13
36	Epidemiology, Risk Factors, and Outcomes of Diffuse Alveolar Hemorrhage After Hematopoietic Stem Cell Transplantation. Chest, 2021, 159, 2325-2333.	0.8	11

#	Article	IF	CITATIONS
37	Post-Marketing Analysis of Peripheral Neuropathy Burden with Newer Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System (FAERS) Mina et al. Peripheral Neuropathy and Proteasome Inhibitors. Turkish Journal of Haematology, 2021, 38, 218-221.	0.5	0
38	Free of malignancy but not of fears: A closer look at Damocles syndrome in survivors of hematologic malignancies. Blood Reviews, 2021, 48, 100783.	5.7	10
39	Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. Transplantation and Cellular Therapy, 2021, 27, 679.e1-679.e8.	1.2	10
40	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplantation and Cellular Therapy, 2021, 27, 921.e1-921.e10.	1.2	11
41	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy. 2021. 27. 642-649.	1.2	65
42	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplantation and Cellular Therapy, 2021, 27, 923.e1-923.e12.	1.2	15
43	Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review. Transplantation and Cellular Therapy, 2021, 27, 738-746.	1.2	4
44	Current status and future perspectives on the Internet of Things in oncology. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	9
45	Blockchain Integration With Digital Technology and the Future of Health Care Ecosystems: Systematic Review. Journal of Medical Internet Research, 2021, 23, e19846.	4.3	20
46	Machine Learning Applications in the Diagnosis of Benign and Malignant Hematological Diseases. Clinical Hematology International, 2021, 3, 13.	1.7	10
47	Recommendations on service delivery to help reduce suffering and anxiety in patients and caregivers post-hematopoietic cell transplantation: a case report. Journal of Medical Case Reports, 2021, 15, 549.	0.8	3
48	Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia. Annals of Saudi Medicine, 2021, 41, 198-205.	1.1	0
49	Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia. Annals of Saudi Medicine, 2021, 41, 198-205.	1.1	2
50	Fecal Microbiota Transplantation As a Therapeutic Option for Graft-Versus-Host-Disease: A Systematic Review and Future Directions. Blood, 2021, 138, 4869-4869.	1.4	1
51	The strange case of Dr. Hashmi and Mr. Hyde. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 244-247.	0.9	Ο
52	Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application. Bone Marrow Transplantation, 2020, 55, 40-47.	2.4	31
53	Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 131-142.	0.9	14
54	Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. Bone Marrow Transplantation, 2020, 55, 698-707.	2.4	4

#	Article	IF	CITATIONS
55	Outcomes of allogeneic hematopoietic cell transplant for acute myeloid leukemia in adolescent patients. Bone Marrow Transplantation, 2020, 55, 182-188.	2.4	3
56	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2020, 26, 472-479.	2.0	21
57	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2020, 26, 553-561.	2.0	13
58	Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury–Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Network Open, 2020, 3, e1918668.	5.9	40
59	Comparison of outcomes of HCT in blast phase of <i>BCR-ABL1</i> â^' MPN with de novo AML and with AML following MDS. Blood Advances, 2020, 4, 4748-4757.	5.2	14
60	Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. Lancet Haematology,the, 2020, 7, e816-e826.	4.6	84
61	Management of chemotherapy-induced alopecia (CIA): A comprehensive review and future directions. Critical Reviews in Oncology/Hematology, 2020, 156, 103093.	4.4	9
62	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer, 2020, 126, 5077-5087.	4.1	47
63	Thank You for Not Smoking. Mayo Clinic Proceedings, 2020, 95, 2062-2064.	3.0	1
64	Management principles in patients with COVID-19: perspectives from a growing global experience with emphasis on cardiovascular surveillance. Open Heart, 2020, 7, e001357.	2.3	6
65	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190.	5.2	18
66	The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis. Hematology/ Oncology and Stem Cell Therapy, 2020, , .	0.9	97
67	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee, Biology of Blood and Marrow Transplantation, 2020, 26, 2181-2189.	2.0	51
68	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2020, 26, 2139-2146.	2.0	14
69	COVID-19: emerging challenges in maintaining physical function in patients who have had haematopoietic cell transplants. International Journal of Therapy and Rehabilitation, 2020, 27, 1-7.	0.3	0
70	Role of testosterone in COVID-19 patients – A double-edged sword?. Medical Hypotheses, 2020, 144, 110287.	1.5	21
71	Screening for SARS-CoV-2. Mayo Clinic Proceedings, 2020, 95, 2606-2608.	3.0	3
72	Unique aspects of Graft-versus-host-disease management in the Eastern Mediterranean region: Report from the Eastern Mediterranean blood and marrow transplantation group: Special report. Hematology/ Oncology and Stem Cell Therapy, 2020, , .	0.9	0

#	Article	lF	CITATIONS
73	Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973.	5.2	63
74	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica, 2020, 105, 1329-1338.	3.5	23
75	Genotypic and Phenotypic Characteristics of Acute Promyelocytic Leukemia Translocation Variants. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 189-201.	0.9	18
76	The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 1747-1756.	2.0	7
77	Comprehensive Genomic Analysis of Noonan Syndrome and Acute Myeloid Leukemia in Adults: A Review and Future Directions. Acta Haematologica, 2020, 143, 583-593.	1.4	4
78	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a â€~̃graft versus host'-like syndrome and poor outcomes. Bone Marrow Transplantation, 2020, 55, 1879-1881.	2.4	1
79	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2020, 26, 1784-1802.	2.0	14
80	Characteristics of late transplantâ€associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2020, 95, 1170-1179.	4.1	19
81	Outcome of hematopoietic stem cell transplantation (HCT) from HLA-matched related donor for Fanconi anemia (FA) in adolescents and adults: a retrospective study by Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT). Bone Marrow Transplantation, 2020, 55, 1485-1490.	2.4	1
82	Follow-up issues in survivors of hematologic malignancies – Current stance and future perspectives. Blood Reviews, 2020, 44, 100674.	5.7	6
83	Can we prevent or treat graft-versus-host disease with cellular-therapy?. Blood Reviews, 2020, 43, 100669.	5.7	13
84	Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic Hematopoietic Cell Transplants. JAMA Dermatology, 2020, 156, 631.	4.1	9
85	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia, 2020, 34, 3338-3347.	7.2	27
86	Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study. Blood, 2020, 136, 22-24.	1.4	24
87	The Increasing Trends in Cases of the Most Common Cancers in Saudi Arabia. Journal of Epidemiology and Global Health, 2020, 10, 258.	2.9	12
88	Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally. Bone Marrow Transplantation, 2019, 54, 383-392.	2.4	30
89	Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care. Blood Reviews, 2019, 33, 63-73.	5.7	38
90	Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends. Bone Marrow Transplantation, 2019, 54, 402-417.	2.4	31

#	Article	IF	CITATIONS
91	Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 73-85.	2.0	35
92	Chronic graftâ€versusâ€host disease: Current management paradigm and future perspectives. Oral Diseases, 2019, 25, 931-948.	3.0	26
93	Machine learning applications in the diagnosis of leukemia: Current trends and future directions. International Journal of Laboratory Hematology, 2019, 41, 717-725.	1.3	74
94	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2305-2321.	2.0	132
95	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2398-2407.	2.0	21
96	Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine, 2019, 47, 446-456.	6.1	697
97	Impact of hospital hospitality house programs on quality of life and mood of patients and caregivers after hematopoietic stem cell transplant. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 155-160.	0.9	1
98	Improved Outcome of a Pediatric-Inspired Protocol for High-Risk Adolescent and Young Adult Acute Lymphoblastic Leukemia Patients Using Peg-Asparaginase and Escalating Dose of Methotrexate: Tolerability and Outcome. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 670-677.	0.4	6
99	Lessons Learned from Large-Scale, First-Tier Clinical Exome Sequencing in a Highly Consanguineous Population. American Journal of Human Genetics, 2019, 104, 1182-1201.	6.2	184
100	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation, 2019, 54, 1868-1880.	2.4	86
101	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. Biology of Blood and Marrow Transplantation, 2019, 25, 2322-2329.	2.0	21
102	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1875-1883.	2.0	14
103	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. Biology of Blood and Marrow Transplantation, 2019, 25, 2330-2337.	2.0	22
104	Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant. JAMA Pediatrics, 2019, 173, e190081.	6.2	14
105	Risks and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with HIV Infection. Biology of Blood and Marrow Transplantation, 2019, 25, e260-e267.	2.0	11
106	Chemotherapyâ€induced skin toxicity and capillary leak syndrome. International Journal of Dermatology, 2019, 58, 856-860.	1.0	4
107	Effects of smoking on outcomes of hematopoietic cell transplantation: a systemic review and future directions. Bone Marrow Transplantation, 2019, 54, 1382-1390.	2.4	3
108	Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant. Biology of Blood and Marrow Transplantation, 2019, 25, 1232-1239.	2.0	6

#	Article	IF	CITATIONS
109	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Advances, 2019, 3, 1826-1836.	5.2	89
110	Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. Blood Advances, 2019, 3, 2525-2536.	5.2	13
111	Registries and artificial intelligence: investing in the future of hematopoietic cell transplantation. Bone Marrow Transplantation, 2019, 54, 477-480.	2.4	7
112	A dynamical systems perspective on chimeric antigen receptor T-cell dosing. Bone Marrow Transplantation, 2019, 54, 485-489.	2.4	6
113	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e76-e85.	2.0	85
114	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2019, 54, 1254-1265.	2.4	47
115	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 480-487.	2.0	10
116	Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine, 2019, 40, 554-563.	6.1	746
117	Role of Physical Therapy before and after Hematopoietic Stem Cell Transplantation: White Paper Report. Biology of Blood and Marrow Transplantation, 2019, 25, e191-e198.	2.0	33
118	Physical therapy pathway and protocol for patients undergoing hematopoietic stem cell transplantation: Recommendations from The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 127-132.	0.9	16
119	Non-Graft-Versus-Host Disease Ocular Complications after Hematopoletic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow	2.0	16
120	Transplantation, 2019, 25, e145-e154. Challenges in managing graft-versus-host disease in developing countries: a perspective. Bone Marrow Transplantation, 2019, 54, 641-647.	2.4	6
121	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. Biology of Blood and Marrow Transplantation, 2019, 25, 270-278.	2.0	21
122	Clinical and histopathological spectrum of toxic erythema of chemotherapy in patients who have undergone allogeneic hematopoietic cell transplantation. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 19-25.	0.9	12
123	Ruxolutinib in Steroid Refractory Graft Versus Host Disease (SR-GVHD): Systemic Literature Review. Blood, 2019, 134, 5682-5682.	1.4	0
124	Approach to pancytopenia: Diagnostic algorithm for clinical hematologists. Blood Reviews, 2018, 32, 361-367.	5.7	35
125	Are graft-versus-host-disease patients missing out on the vital occupational therapy services? a systematic review. International Journal of Rehabilitation Research, 2018, 41, 110-113.	1.3	3
126	Damocles' syndrome revisited: Update on the fear of cancer recurrence in the complex world of today's treatments and survivorship. Hematology/ Oncology and Stem Cell Therapy, 2018, 11, 129-134.	0.9	28

#	Article	IF	CITATIONS
127	Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. Leukemia and Lymphoma, 2018, 59, 2737-2739.	1.3	9
128	Does matching for SNPs in the MHC gamma block in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant improve outcomes?. Human Immunology, 2018, 79, 532-536.	2.4	6
129	Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 1546-1553.	2.0	40
130	Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. Leukemia, 2018, 32, 1414-1420.	7.2	20
131	Thyroid dysfunction in adult hematopoietic cell transplant survivors: risks and outcomes. Bone Marrow Transplantation, 2018, 53, 977-982.	2.4	15
132	â€~To treat or not to treat': raising awareness on the effects of graft versus host disease drugs on musculoskeletal system. Bone Marrow Transplantation, 2018, 53, 909-912.	2.4	3
133	Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia: clinical characteristics, incidence, risk factors and outcomes. Bone Marrow Transplantation, 2018, 53, 838-843.	2.4	10
134	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 932-937.	2.4	1
135	Detection of secondary malignancy following high-dose chemotherapy in germ cell tumors: prospects and limitations. Bone Marrow Transplantation, 2018, 53, 661-663.	2.4	Ο
136	Full-body physical therapy evaluation for pre- and post-hematopoietic cell transplant patients and the need for a modified rehabilitation musculoskeletal specific grading system for chronic graft-versus-host disease. Bone Marrow Transplantation, 2018, 53, 625-627.	2.4	7
137	Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities. Cancer, 2018, 124, 1710-1721.	4.1	40
138	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 945-955.	2.0	7
139	Hematopoietic stem cell transplantation for adult sickle cell disease in the era of universal donor availibility. Bone Marrow Transplantation, 2018, 53, 1390-1400.	2.4	5
140	Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions. Biology of Blood and Marrow Transplantation, 2018, 24, 1906-1913.	2.0	21
141	ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. Biology of Blood and Marrow Transplantation, 2018, 24, 1119-1124.	2.0	33
142	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, 1928-1935.	2.0	2
143	Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, 1920-1927.	2.0	40
144	Prognostic role of KIR genes and HLA-C after hematopoietic stem cell transplantation in a patient cohort with acute myeloid leukemia from a consanguineous community. Bone Marrow Transplantation, 2018, 53, 1170-1179.	2.4	11

#	Article	lF	CITATIONS
145	Long-Term Follow-Up Program. , 2018, , 231-243.		2
146	Individualizing Optimal Dosing of Antithymocyte Globulin in Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2-3.	2.0	2
147	Artificial Intelligence approaches in hematopoietic cell transplant: A review of the current status and future directions. Turkish Journal of Haematology, 2018, 35, 152-157.	0.5	8
148	Haploidentical Stem Cell Transplantation: A Gateway to Infrequent Availability of HLA-Matched Related Donors. Case Reports in Medicine, 2018, 2018, 1-4.	0.7	2
149	Determining the Quantitative Principles of T Cell Response to Antigenic Disparity in Stem Cell Transplantation. Frontiers in Immunology, 2018, 9, 2284.	4.8	11
150	Vaccinating donors for hematopoietic cell transplantation: A systematic review and future perspectives. Vaccine, 2018, 36, 6043-6052.	3.8	3
151	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. Blood Advances, 2018, 2, 1022-1031.	5.2	13
152	Philadelphia-like acute lymphoblastic leukemia: diagnostic dilemma and management perspectives. Experimental Hematology, 2018, 67, 1-9.	0.4	14
153	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leukemia Research, 2018, 74, 130-136.	0.8	47
154	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biology of Blood and Marrow Transplantation, 2018, 24, 2443-2449.	2.0	11
155	Relationship between Aging and Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1965-1970.	2.0	10
156	Lost to Follow-up Rates Are Higher in Pediatric Than Adult Survivors, but Not By Transplant Type: A Report from the Center for International Blood and Marrow Transplant Research. Blood, 2018, 132, 2260-2260.	1.4	3
157	A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results. Blood, 2018, 132, 1443-1443.	1.4	0
158	Histopathologic Acute Lung Injury after Allogeneic Hematopoietic Cell Transplantation: Clinical Findings, Radiologic Features, Treatments and Outcomes. Blood, 2018, 132, 2113-2113.	1.4	0
159	Proteomics Analysis Reveals Protein Panels That Are Associated with Prediction to Tyrosine Kinase Inhibitors Response, Bone Marrow Transplant, Survival and Disease Outcome of Chronic Myeloid Leukemia Patients. Blood, 2018, 132, 5434-5434.	1.4	0
160	Gene Therapy for Thalassemia and Sickle Cell Anemia Poses Acceptable Toxicity and Efficacy: Clinical Outcomes in Forty-Seven Cases. Blood, 2018, 132, 2194-2194.	1.4	0
161	The Impact of Early Post-Transplant Cyclosporine Induced Acute Nephrotoxicity on Long Term Renal Function in 2-Year Survivors of Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Retrospective Study. Blood, 2018, 132, 3358-3358.	1.4	0
162	A Clinical, Genomic and Proteomic Approach for the Characterization of Fanconi Anemia in Adolescent and Young Adult (AYA) Patients : A Single Center Study of 55 Patients from a National Bone Marrow Failure Referral Center. Blood, 2018, 132, 2594-2594.	1.4	7

#	Article	IF	CITATIONS
163	Estimating the annual volume of hematologic cancer cases per hematologist–oncologist in the United States: are we treating rare cancers too rarely?. Leukemia and Lymphoma, 2017, 58, 251-252.	1.3	6
164	A systematic review of religious beliefs about major end-of-life issues in the five major world religions. Palliative and Supportive Care, 2017, 15, 609-622.	1.0	107
165	Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer. Breast Cancer Research and Treatment, 2017, 164, 515-525.	2.5	9
166	Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. Biology of Blood and Marrow Transplantation, 2017, 23, 1327-1334.	2.0	38
167	Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. Cancer, 2017, 123, 3141-3149.	4.1	65
168	Sex-based disparities in venous thromboembolism outcomes: A National Inpatient Sample (NIS)-based analysis. Vascular Medicine, 2017, 22, 121-127.	1.5	18
169	Improved survival after acute graft- <i>versus</i> -host disease diagnosis in the modern era. Haematologica, 2017, 102, 958-966.	3.5	79
170	Immunophenotypic and molecular comparison between allogeneic and autologous graftâ€vsâ€host disease of the skin: A retrospective study using immunohistochemical and proteomics methods. Journal of Cutaneous Pathology, 2017, 44, 1087-1091.	1.3	2
171	Cost and quality issues in establishing hematopoietic cell transplant program in developing countries. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 167-172.	0.9	27
172	Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a <scp>SEER</scp> â€medicare analysis. Cancer Medicine, 2017, 6, 2876-2885.	2.8	63
173	Clinical outcomes of <scp>HLA</scp> â€ <scp>DPB</scp> 1 mismatches in 10/10 <scp>HLA</scp> â€matched unrelated donorâ€recipient pairs undergoing allogeneic stem cell transplant. European Journal of Haematology, 2017, 99, 275-282.	2.2	11
174	Establishing an autologous versus allogeneic hematopoietic cell transplant program in nations with emerging economies. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 173-177.	0.9	6
175	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood, 2017, 130, 1156-1164.	1.4	210
176	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, 6-9.	2.0	49
177	Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. Leukemia and Lymphoma, 2017, 58, 872-881.	1.3	29
178	Cutaneous manifestations of graftâ€versusâ€host disease: role of the dermatologist. International Journal of Dermatology, 2017, 56, 131-140.	1.0	28
179	National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report. Biology of Blood and Marrow Transplantation, 2017, 23, 717-725.	2.0	40
180	Biology of premature ageing in survivors of cancer. ESMO Open, 2017, 2, e000250.	4.5	148

#	Article	IF	CITATIONS
181	Hitting the Holy Grail of Hematopoietic Cell Transplantation with Naive T-Cell Depleted Allografts—Graft Engineered Hematopoietic Stem Cell Transplant. Biomedicines, 2017, 5, 48.	3.2	Ο
182	Medical Students' Knowledge, Familiarity, and Attitudes towards Hematopoietic Stem Cell Donation. Biology of Blood and Marrow Transplantation, 2016, 22, 1710-1716.	2.0	24
183	Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets. Leukemia Research Reports, 2016, 5, 7-10.	0.4	13
184	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 1056-1064.	2.0	26
185	Venous thromboembolism following hematopoietic stem cell transplantation—a systematic review and meta-analysis. Annals of Hematology, 2016, 95, 1457-1464.	1.8	48
186	Strategies and Challenges in Clinical Trials Targeting Human Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 1424-1434.	3.6	111
187	Employment Status as an Indicator of Recovery and Function One Year after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1690-1695.	2.0	51
188	Vancomycinâ€resistant <i><scp>E</scp>nterococcus</i> colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Transplant Infectious Disease, 2016, 18, 913-920.	1.7	40
189	Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy. European Journal of Haematology, 2016, 97, 313-320.	2.2	21
190	Frameworks for Proof-of-Concept Clinical Trials of Interventions That Target Fundamental Aging Processes. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 1415-1423.	3.6	66
191	Basics of Hematopoietic Cell Transplantation for Primary Care Physicians and Internists. Primary Care - Clinics in Office Practice, 2016, 43, 693-701.	1.6	4
192	Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. Biology of Blood and Marrow Transplantation, 2016, 22, 1431-1439.	2.0	26
193	Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy. International Journal of Hematology, 2016, 103, 409-415.	1.6	Ο
194	ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLAâ€matched peripheral blood hematopoietic cell transplantation after reducedâ€intensity conditioning. Transfusion, 2016, 56, 518-527.	1.6	14
195	Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2016, 57, 1714-1715.	1.3	7
196	Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematology,the, 2016, 3, e45-e52.	4.6	158
197	The Incidence and Severity of Oral Mucositis among AllogeneicÂHematopoietic Stem Cell Transplantation Patients: A Systematic Review. Biology of Blood and Marrow Transplantation, 2016, 22, 605-616.	2.0	103
198	Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole. Biology of Blood and Marrow Transplantation, 2016, 22, 579-583.	2.0	19

#	Article	IF	CITATIONS
199	Racial Disparity in Drug Utilization Among Multiple Myeloma Patients: A SEER Medicare Analysis. Blood, 2016, 128, 3542-3542.	1.4	1
200	Trends in Disease Presentation, Management, Cost of Care and Outcomes: A Comprehensive Look at Racial Disparities in Multiple Myeloma (MM). Blood, 2016, 128, 3544-3544.	1.4	3
201	Real-World Data Indicates That the Addition of Etoposide to Idarubicin and Cytarabine (3+7) Induction in Young Adults (<60 years) with AML Does Not Improve Survival or Remission Rates. Blood, 2016, 128, 4010-4010.	1.4	1
202	Addition of ATG to Myeloablative Haplo Conditioning with Post-Transplantation Cyclophosphamide Might Decrease the Risk of Gvhd and TRM without Increasing the Risk of Relapse. Blood, 2016, 128, 5871-5871.	1.4	8
203	Prevalence and survival of smoldering multiple myeloma in the US: Analysis using a national dataset Journal of Clinical Oncology, 2016, 34, 8035-8035.	1.6	0
204	Acute care use among women receiving adjuvant chemotherapy for breast cancer Journal of Clinical Oncology, 2016, 34, 6543-6543.	1.6	0
205	Sex-Based Disparities in Venous Thromboembolism Sociodemographics and Outcomes: A National Inpatient Sample (NIS)-Based Analysis. Blood, 2016, 128, 5918-5918.	1.4	1
206	Disparities in the Upfront Use of Hematopoietic Stem Cell Transplant Among Patients with Acute Myeloid Leukemia. Blood, 2016, 128, 3543-3543.	1.4	0
207	Sexual health in hematopoietic stem cell transplant recipients. Cancer, 2015, 121, 4124-4131.	4.1	50
208	A perspective on complementary/alternative medicine use among survivors of hematopoietic stem cell transplant: Benefits and uncertainties. Cancer, 2015, 121, 2303-2313.	4.1	15
209	Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: AASingle-Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 699-704.	0.4	11
210	Lost in Transition: The Essential Need for Long-Term Follow-Up Clinic for Blood and Marrow Transplantation Survivors. Biology of Blood and Marrow Transplantation, 2015, 21, 225-232.	2.0	85
211	Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition in Myeloid Malignancies. Blood, 2015, 126, 1347-1347.	1.4	7
212	Early T-Lymphocyte Chimerism Kinetics Is Influenced By Conditioning Regimen in Reduced Intensity Allogeneic Stem Cell Transplantation. Blood, 2015, 126, 1923-1923.	1.4	1
213	Prognostic Impact of Peripheral Blood Count Recovery and Cytogenetic Remission Prior to Reduced Intensity Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndromes. Blood, 2015, 126, 3210-3210.	1.4	1
214	Fludarabine Busulfan Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing. Blood, 2015, 126, 736-736.	1.4	2
215	Estimating the Annual Volume of Hematologic Cancer Cases per Hematologist-Oncologist in the United States: Are We Treating Rare Cancers Too Rarely?. Blood, 2015, 126, 3297-3297.	1.4	0
216	A Phase II of Combination D aunorubicin and Cytarabine (A ra-c) and Nilotinib (TA signa) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Interim Results. Blood, 2015, 126, 3808-3808.	1.4	0

#	Article	IF	CITATIONS
217	Clofarabine Based Chemotherapy in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma-a Single Institution Experience. Blood, 2015, 126, 4910-4910.	1.4	Ο
218	Early CMV Infection Detected By Quantitative Nucleic Acid Testing (QNAT) Is Associated with Lower Risk of Relapse after Reduced Intensity, but Not Myeloablative, Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Blood, 2015, 126, 1913-1913.	1.4	0
219	Clinical Outcome of Hypomethylating Agents in Hypocellular MDS: Mayo Clinic Experience. Blood, 2015, 126, 5254-5254.	1.4	ο
220	The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. Blood, 2015, 126, 4370-4370.	1.4	0
221	Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Research, 2014, 49, 100.	1.3	56
222	Financial Burden in Recipients of Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1375-1381.	2.0	112
223	Cost Effectiveness Decision Tree Analysis of Early Versus Late Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) in the United States (US). Biology of Blood and Marrow Transplantation, 2013, 19, S130-S131.	2.0	2
224	The hematopoietic cell transplantation specific comorbidity index and survival after extracorporeal photopheresis, pentostatin, and reduced dose total body irradiation conditioning prior to allogeneic stem cell transplantation. Leukemia Research, 2013, 37, 1052-1056.	0.8	6
225	Extracorporeal Photophoresis (ECP) For Chronic Graft Versus Host Disease (cGVHD): A Systemic Review and Meta-Analysis. Blood, 2013, 122, 5472-5472.	1.4	Ο
226	A Novel Prognostic Model To Predict Relapse After Allogeneic Stem Cell Transplantation For Myelodysplastic Syndromes. Blood, 2013, 122, 2098-2098.	1.4	0
227	Correlation Of Outcomes Of Allogeneic Stem Cell Transplants For Chronic Myelomonocytic Leukemia With The Mayo Prognostic Model. Blood, 2013, 122, 5226-5226.	1.4	Ο
228	Voriconazole Exposure and The Risk Of Cutaneous Squamous Cell Carcinoma In Allogeneic Hematopoietic Stem Cell Transplant Patients. Blood, 2013, 122, 916-916.	1.4	0
229	Chronic Graft Vs Host Disease Is The Strongest Predictor Of Outcome After Reduced Intensity Conditioning Stem Cell Transplantation In Chronic Lymphocytic Leukemia and Is Associated With Pretransplant B Cell Characteristics. Blood, 2013, 122, 3375-3375.	1.4	0
230	Financial Burden In Recipients Of Allogeneic Hematopoietic Cell Transplantation. Blood, 2013, 122, 721-721.	1.4	1
231	The great Lazarâ \in "a Graft-versus-host-disease patient!. Bone Marrow Transplantation, 0, , .	2.4	0